Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Voyager Therapeutics (VYGR – Research Report). The associated price target remains the same with $9.00.
Yun Zhong has given his Buy rating due to a combination of factors surrounding Voyager Therapeutics’ promising developments in Alzheimer’s disease treatments. The company is advancing its tau-targeting programs, with upcoming data presentations expected in 2025. Notably, their tau silencing gene therapy, VY1706, has shown significant mRNA knockdown in non-human primates, indicating potential efficacy and good tolerability.
Furthermore, Voyager Therapeutics has a solid financial position, ending the fiscal year 2024 with $332.4 million in cash, which is projected to sustain operations until mid-2027. The company’s ongoing studies, including the evaluation of their anti-tau antibody VY7523 in Alzheimer’s patients, have demonstrated positive preliminary results. These factors, combined with the potential for further milestone payments, underpin Yun Zhong’s optimistic outlook and Buy rating for the stock.
In another report released today, Wells Fargo also maintained a Buy rating on the stock with a $10.00 price target.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year.